Supplementary Files

LincCCAT1 Promotes Breast Cancer Stem Cell Function Through Activating WNT/β-catenin Signaling

Tingting Tang¹, Changying Guo¹, Tiansong Xia³, Rui Zhang⁴, Ke Zen³, Yi Pan¹,*, Liang Jin¹,*

Supplementary Data list
Supplementary Materials and Methods
Supplementary Figure and Table legends

Supplementary Figures:
Supplementary Figure S1
Supplementary Figure S2
Supplementary Figure S3
Supplementary Figure S4
Supplementary Figure S5
Supplementary Figure S6
Supplementary Figure S7
Supplementary Figure S8
Supplementary Figure S9
Supplementary Figure S10

Supplementary Spreadsheets:
Supplementary Table S1
Supplementary Table S2
Supplementary Table S3
Supplementary Table S4

Gel

Cell lines authentication report
Supplementary Materials and Methods

RNA isolation and qRT-PCR analysis

Total RNA was isolated using TRIzol (Invitrogen) and a RNeasy kit (QIAGEN, Duesseldorf, Germany) with DNase I digestion according to the manufacturers’ instructions. Reverse transcription reaction was performed using PrimeScriptTM RT reagent Kit (Takara, Tokyo, Japan) and diluted cDNA was used for qRT-PCR analysis using SYBR Premix Ex Taq II Kit (Takara) with the appropriate primers listed in Supplementary Table S4. For microRNA, stem-loop reverse transcription reactions were performed and the $2^{-\Delta \Delta C_{T}}$ method was used to calculate the relative abundance of RNA genes compared with GAPDH or U6 expression.

Flow cytometry and cell sorting

Cells were stained using different antibodies according to the manufacturer’s instructions. Labeled cells were detected using a FACSCalibur (BD Immunocytometry Systems, San Jose, CA). For cell sorting, cocktail PE-conjugated anti-human CD24, APC-conjugated anti-human CD44 and PE/Cy7-conjugated CD326 antibodies were incubated with MCF-7 cells or MDA-MB-231 cells, followed by sorting with FACS Aria III (BD). Antibodies used are provided in Supplementary Table S5.

In vitro Transcription Assays and RNA pull-down assays

RNA pull-down was performed as previously described. Briefly, in vitro translation assays were performed using T7 RNA Polymerase transcription kit according to the manufacturer instruction (Thermo, MA, USA), total RNA treated with RNase-free DNase I (Roche, Basel, Switzerland) and then purified with RNeasy Mini Kit (QIAGEN). Then LncCCAT1 RNAs were labeled by Desthiobiotinylilation by using Pierce RNA 3 End Desthiobiotinylilation Kit (Thermo). Biotinylated RNAs were incubated with cytoplasmic extract of MCF-7 cells at room temperature for 1h. Washed streptavidin agarose beads (Invitrogen) were added to each binding reaction and incubated at room temperature for 1h. Precipitates were washed for three times, boiled in SDS buffer and subjected to SDS–polyacrylamide gel electrophoresis. Specific bands were excised and analyzed by mass spectrometry or subjected to western blotting.

Bisulphite sequencing.

Genomic DNA was extracted from breast cancer cells and subjected to sodium bisulphite modification using EpiTect Bisulfite Kits (QIAGEN) following the manufacturer’s protocols. Sodium bisulphite-treated DNA was
PCR amplified using primers predicted on MethPrimer website and EpiTaq™HS (Takara) was used for bisulphite PCR. The PCR products in each group were cloned into the T-Vector pMD19 (Takara), and over 10 clones were sequenced.

**Cytosolic/nuclear fractionation.**

The separation of the nuclear and cytosolic fractions was performed using the PARIS Kit (Life Technologies, CA, USA) according to the manufacturer’s instructions. Cells were incubated with hypotonic buffer (25mM Tris–HCl, pH 7.4, 1mM MgCl₂ and 5mM KCl) on ice for 5min. An equal volume of hypotonic buffer containing 1% NP-40 was then added, and the sample was left on ice for another 5min. After centrifugation at 5,000g for 5min, the supernatant was collected as the cytosolic fraction. The pellets were resuspended in nuclear resuspension buffer (20 mM HEPES, pH 7.9), 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1mM dithiothreitol and 1mM phenylmethyl sulfonyl fluoride and incubated at 4 °C for 30min. The nuclear fraction was collected after removal of insoluble membrane debris by centrifugation at 12,000g for 10min.

**Western blotting analysis**

Cells proteins were separated by SDS-PAGE electrophoresis and then transferred to a polyvinylidene difluoride membrane. Membranes were immunblotted with primary antibodies and detected with horseradish peroxidase-conjugated anti-IgG. Then membranes were visualized with an enhanced chemiluminescence kit (Tanon, Shanghai, China). Antibodies used in the western blotting are provided in Supplementary Table S5.

**Plasmid construction**

LncCCAT1, ANXA2 and TCF4 cDNA were amplified by using Super-Fidelity DNA Polymerase (Vazyme, Nanjing, China) and cloned into the expression vector pcDNA3.1 (Invitrogen). The five LncCCAT1 fragments for RNA pull down assays used pcDNA3.1-CCAT1 as a template for generating constructs carrying deletions using respective primers and named S1-S5. The pcDNA3.1-CCAT1 with point mutations in the miR-148a/152 and miR-204/211 response elements was synthesized by GeneCreate (Wuhan, China) and named pcDNA3.1-CCAT1-MUT. pcDNA3.1-MS2-12X (Addgene) was double digested with EcoR I and Xho I, and the MS2-12X fragment was subcloned into pcDNA3.1, pcDNA3.1-CCAT1 and pcDNA3.1-CCAT1-MUT, named pcDNA3.1-MS2, pcDNA3.1-MS2-CCAT1 and pcDNA3.1-MS2-CCAT1-MUT respectively. For Luciferase reporter assay, the 59-nt region of either LncCCAT1, LncCCAT1-MUT (miR-148a/152) and LncCCAT1-MUT (miR-204/211)
was synthesized and subcloned into the pmirGLO vector (Promega, Madison, WI). The 3’ untranslated regions (3’-UTR) of TCF4 mRNA containing the intact miR-204/211 recognition sequences were PCR-amplified and subcloned into pmirGLO vector. All PCR products were verified by DNA sequencing. Primers used for plasmid construction are listed in Supplementary Table S4.

**Knockdown by siRNAs**

siRNAs targeting FAT4, DNMT1, ANXA2, TCF4 were designed and synthesized by Ribo (Guangzhou, China). For transient knockdown LncCCAT1, RiboTM LncRNA Smart Silencer (Ribo) was used, which is a pool containing three siRNA and three antisense oligonucleotides (Supplementary Table S6).

**Proliferation, migration and Invasion assay**

The capacity of cellular proliferation was measured using the Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan) and EdU Cell Proliferation Assay Kit (Ribobio, Guangzhou, China) according to the manufacturer’s instructions. The optical density was determined with a microplate reader at a wavelength of 450 nm. To analyze the migration and invasion abilities of cells, transwell migration assay and transwell invasion assay was performed based on published method. For the cell transmembrane migration assay, all the steps were carried out similarly to those in the invasion assay except for the Matrigel (BD Biosciences, San Jose, CA, USA) coating. After incubation at 37˚C for 24 h, the filters were removed. The cells adhering to the lower surface were fixed and stained with Crystal Violet, 10 randomly selected fields in each well were counted. n=3, Magnification was 200×.

**Luciferase reporter assay**

pmirGLO, pmirGLO-CCAT-WT or pmirGLO-CCAT-MUT (miR-148a/152, miR-204/211) was co-transfected with pre miR-148a/152, pre miR-204/211 mimics or miR-NC into MCF-7 cells by Lipofectamine-mediated gene transfer. pmirGLO, pmirGLO-TCF4-WT or pmirGLO-TCF4-MUT was transfected into MCF-7 cells by lipofectamine-mediated gene transfer. The relative luciferase activity was normalized to Renilla luciferase activity 48h after transfection.

**Cell transfection and Lentivirus production**

Transfections were performed using the Lipofectamine 2000 kit (Invitrogen) according to the manufacturer’s
instructions. The double-stranded microRNA mimics and their respective negative control RNAs (GenePharma, Shanghai, China) were transfected into cells at a final concentration of 50 nM. The cells were harvested at 48h after transfection. Recombinant lentiviruses containing pre-hsa-miR-148a, pre-hsa-miR-204, hsa-miR-148a inhibitor, hsa-miR-152 inhibitor or the control were purchased from (GenePharma). For stable overexpression, the cDNA of LncCCAT1, TCF4 and ANXA2 genes were cloned into the lentiviral expression vector pLVX-IRES-ZsGreen1 (Addgene). To produce lentivirus, HEK-293T cells were co-transfected with the lentiviral vector and packaging vectors psPAX2 and pMD2.G using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s guidelines. Infectious lentiviruses were harvested at 48h post transfection and filtered through 0.45μm PVDF filters and the recombinant lentiviruses were concentrated 100-fold by ultracentrifugation (3 h at 50,000 g). The virus-containing pellet was dissolved in DMEM, aliquoted and stored at -80°C. Based on the shRNA sequences provided above, the most effective shRNAs were used for subsequent studies. shRNAs against ANXA2, TCF4 and control hairpins were cloned into pLVX-shRNA2 vector as described above, the virus supernatant was collected and cells were transfected with lentiviral constructs expressing as described above for 24h. The expression of LncCCAT1, ANXA2 and TCF4 in the infected cells was collected for protein and RNA analysis 96h after infection.

**Fluorescence in situ hybridization (FISH) and LNA based in situ hybridization (LNA ISH)**

Cy3 labeled LncCCAT1 probe was designed and synthesised by (Ribo, Guangzhou, China). For FISH assay, cells were fixed in 4% formaldehyde and permeabilized with 0.5% Triton X-100 for 5 min, washed with PBS three times and once in 2× SSC buffer. Hybridization was carried out using DNA probe sets at 37°C for 12 h. Images were obtained with confocal laser microscope (Carl Zeiss, Oberkochen, Germany). In situ hybridization (ISH) was performed by applying the ISH Kit (Boster, Bio-Engineering Company, Wuhan, China). Formalin-fixed paraffin embedded (FFPE) tissue slides were deparaffinized and deproteinated. Slides were then prehybridized in prehybridization solution for 2 h at 42 °C and incubated in DIG-labeled probe solution over night at 42°C. After stringent washing, the slides were exposed to a streptavidin-peroxidase reaction system and stained with 3, 3′diaminobenzidine (DAB, ZSGB-BIO, Beijing, China). Hematoxylin (Sigma) was used to counterstain the slides.

**The copy number of LncCCAT1 and miRNAs per cell**

The standard curves were formulated with limit dilution approaches using LncCCAT1 expressing vector
pcDNA3.1-LncCCAT1 and reverse transcribed miR-204/211/148a/152 cDNA as standard templates, and then the exact copy numbers of LncCCAT1 and miR-204/211/148a/152 per cell were calculated according to cell counts and molecular weights.

**TOP-Flash reporter assay**

Cells were transfected with 200 ng of the TOP-FLASH or FOP-FLASH reporter constructs together with 20 ng of the Renilla luciferase vector. Luciferase activity was measured by the Dual–Luciferase Reporter Assay System (Promega) 48 h after transfection, and TOP or FOP values were normalized to Renilla values. The TOP/FOP ratios were calculated and used as indicators of the endogenous level of WNT signaling. The experiment was repeated twice and the result was reproducible.

**Supplementary Figure and Table legends**

**Supplementary Figure S1. Verification of LncCCAT1 overexpression, KD and KO efficiencies of oeLncCCAT1, si-LncCCAT1 and CRISPR/Cas9, respectively.** (A) TCGA database indicated that LncCCAT1 was correlated with a poor survival rate in patients with Luminal A breast cancer (Kaplan-Meier survival analysis). (B, C) LncCCAT1 overexpression efficiencies by transfecting LncCAT1 plasmid (B) and LncCCAT1 lentivirus (C) in MCF-7 and MDA-MB-231 cells detected by qRT-PCR. (D) LncCCAT1 knockdown efficiency after transfection of MCF-7 and MDA-MB-231 cells with LncCCAT1 siRNAs. (E-H) Generation of LncCCAT1-KO breast cancer cells by CRISPR/Cas9. Knockout strategy with gRNA sequences (gRNA-1), and relative positions of primers (F1/R1) used for genomic PCR and primers (F2/R2) used for detecting deletions (E). Identification of KO clones by genomic PCR (F). Detection of LncCCAT1 in KO clones by qRT-PCR (G). Nucleotide sequences of three clones involving deletions (H). *P<0.05, **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

**Supplementary Figure S2. LncCCAT1 promotes breast cancer cell stemness and migration in vitro.**

(A) Percentage of CD44+CD24- or CD44+CD24-ESA+ cells in LncCCAT1-overexpressing adherent cells and LncCCAT1-KO spheroid cells of MCF-7 cells or MDA-MB-231 cells, respectively, detected by flow cytometric analysis. (B) mRNA levels of pluripotent transcription factors in LncCCAT1-overexpressing MCF-7 and MDA-MB-231 cells and LncCCAT1-knockdown MCF-7 and MDA-MB-231 spheroid cells. (C, D) The migration abilities of LncCCAT1-overexpressing adherent cells and LncCCAT1-KO spheroid cells of MCF-7 cells (C) or
MDA-MB-231 cells (D) detected by wound healing assay. Scale bar, 100 μm. **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

Supplementary Figure S3. Verification of MS2-LncCCAT1 overexpression, overexpression and KD efficiencies of miR-204/211, miR-148a/152, respectively.

(A) Expression (a) and distribution (b) of LncCCAT1 in MCF-7 cells transfected with either pcDNA3.1-MS2 or pcDNA3.1-MS2-CCAT1. (B) Enrichment of predicted miRNAs in RNAs retrieved from MS2-LncCCAT1 compared with control in MCF-7 cells detected by MS2-based RIP assay with anti-GFP antibody. (C, D) miR-204/211(C) or miR-148a/152(D) overexpression or knockdown efficiencies by transfecting miRNA mimics (left) and miRNAs inhibitors (right) in MCF-7 and MDA-MB-231 cells detected by qRT-PCR. All data are shown as the mean±SD. *P<0.05, **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

Supplementary Figure S4. Expression levels of miR-204 and miR-211 in breast cancer tissues and cells.

(A, B) miR-204 (A) and miR-211 (B) levels were detected in 80 pairs of breast cancer tissues by qRT-PCR. The levels of miR-204/211 in breast cancer tissues were significantly higher than in adjacent normal tissues. (C) miR-204 and miR-211 levels were detected in adherent cells, spheroid cells, non-BCSCs and BCSCs of MCF-7 and MDA-MB-231 cells by qRT-PCR analysis. Relative gene expression values were normalized to those of endogenous U6. (D) miR-204 and miR-211 levels in LncCCAT1-overexpressing or knockdown or LncCCAT1-MUT-overexpressing MCF-7 cells detected by qRT-PCR analysis. Relative gene expression values were normalized to endogenous U6. (E) TCF4 mRNA levels were not altered after transfection with miR-204/211 mimic or miR-204/211 inhibitor in MCF-7 or MDA-MB-231 cells. All data are shown as the mean±SD. *P<0.05, **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

Supplementary Figure S5. TCF4 promotes breast cancer cell proliferation, self-renewal, migration, and invasion in vitro. (A, B) TCF4 overexpression (A) and knockdown (B) efficiencies by transfecting TCF4 plasmid or si-TCF4 in MCF-7 or MDA-MB-231 cells detected by qRT-PCR (left) and western blotting (right). (C) Proliferative abilities of TCF4-overexpressing MCF-7 cells and LncCCAT1-knockdown MDA-MB-231 cells detected by CCK-8 assays. (D) Sphere-formation abilities of TCF4-overexpressing MCF-7 cells and TCF4-knockdown MDA-MB-231 cells. The sphere-formation efficiencies (SFEs) are shown on the right. Scale bar, 100 μm. (E) Migration (upper) and invasion (lower) abilities of TCF4-overexpressing MCF-7 cells and
LncCCAT1-knockdown MDA-MB-231 cells detected by transwell migration and invasion assays. Scale bar, 100 µm. All data are shown as the mean±SD. *P<0.05, **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

Supplementary Figure S6. Expression levels of miR-148a and miR-152 in breast cancer tissues and cells. (A, B) miR-148a (A) and miR-152 (B) levels were detected in 80 pairs of breast cancer tissues by qRT-PCR. The levels of miR-148a/152 in breast cancer tissues were significantly higher than those in adjacent normal tissues. (C) miR-148a and miR-152 levels were detected in adherent cells, spheroid cells, non-BCSCs and BCSCs of MCF-7 and MDA-MB-231 cells by qRT-PCR analysis. Relative gene expression values were normalized to those of endogenous U6. (D) miR-148a and miR-152 levels in LncCCAT1-overexpressing or knockdown or LncCCAT1-MUT-overexpressing MCF-7 cells detected by qRT-PCR analysis. Relative gene expression values were normalized to endogenous U6. All data are shown as the mean±SD. *P<0.05, **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

Supplementary Figure S7. LncCCAT1 inhibits FAT4 expression through upregulation of DNMT1. (A, B) mRNA levels of potential genes downregulated by both LncCCAT1 and DNMT1 in MCF-7 (A) and MDA-MB-231 (B) cells transfected with LncCCAT1, LncCCAT1 plus si-DNMT1, and LncCCAT1 together with 5 µM 5-Aza. (C, D) FAT4 knockdown efficiency following transfection with FAT4 siRNAs in MCF-7 (C) and MDA-MB-231 cells (D) detected by qRT-PCR (left) and western blotting (right). All data are shown as the mean±SD. *P<0.05, **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

Supplementary Figure S8. ANXA2 promotes breast cancer cell proliferation, self-renewal, migration, and invasion in vitro. (A) MS/MS profiles of the ANXA2 band retrieved by LncCCAT1. The corresponding peptide sequences are listed on the top of the graphs. (B) ANXA2 protein levels were not altered after transfection with oeLncCCAT1 or si-LncCCAT1 in MCF-7 (left) or MDA-MB-231 (right) cells as detected by western blotting. (C) ANXA2 overexpression and knockdown efficiencies by transfecting ANXA2 lentivirus or sh-ANXA2 lentivirus in MCF-7 (left) or MDA-MB-231 (right) cells detected by qRT-PCR (upper) and western blotting (lower). (D) Proliferative abilities of ANXA2-overexpressing MCF-7 cells and ANXA2-knockdown MDA-MB-231 cells detected by CCK-8 assays. (E) Sphere-formation abilities of ANXA2-overexpressing MCF-7 cells and ANXA2-knockdown MDA-MB-231 cells. The sphere-formation efficiencies (SFEs) are shown on the
right. Scale bar, 100 μm. (F) Migration (upper) and invasion (lower) abilities of ANXA2-overexpressing MCF-7 cells and ANXA2-knockdown MDA-MB-231 cells detected by transwell assays. Scale bar, 100 μm. (G) Protein levels of crucial genes involved in the Wnt/β-catenin signaling pathway and EMT in MCF-7 (left) and MDA-MB-231 (right) cells transfected with oeANXA2 or si-ANXA2 detected by western blotting. All data are shown as the mean±SD. *P<0.05, **P<0.01, and ***P<0.001 by two-tailed Student’s t-test.

Supplementary Figure S9. LncCCAT1 promotes breast cancer cells stemness in vivo by binding miR-204/211, miR-148a/152 and ANXA2. (A-C) Images (A) of tumors and index (B,C) of tumors harvested after serially diluted different MCF-7 cells were planted. (D) Representative immunohistochemical staining of Nanog, Sox2, Oct4, ALDH1A1, CD44 and CD24 of the tumors from subcutaneously implanted mice. Scale bar, 100 μm.

Supplementary Figure S10. Representative immunohistochemical staining of Wnt target genes including c-Myc, c-Jun, LEF1, MMP-7, Cyclin D1, TCF1/TCF7 and Axin2 of the tumors from subcutaneously implanted mice. Scale bar, 100 μm.

Supplementary Table S1. LncCCAT1 expression and clinicopathological features in 80 patients with breast cancer.

Supplementary Table S2. Sequences of primers used for qRT-PCR, plasmid construction and ChIP-qPCR.

Supplementary Table S3. Antibodies used for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF) and flow cytometry (FC).

Supplementary Table S4. Sequences of siRNAs and sgRNAs against specific targets.
Supplementary Figure S1

A  Luminal A

Survival rate

B  

Relative LncCCAT1 expression

C  

Relative LncCCAT1 expression

D  

Relative LncCCAT1 expression

E  

F  

G  

H  WT

KO-1

KO-2

...TGCTGTTCTTTTGAGGCCATTCAAGGCTTAATGACTA6CTGCTGTGAAATTCTTTAAACTTTTAGGCCGAGGCACTA...200bp...TTAGCTGACCATCTGGGAAAGGCGCTGTATTTCGACTGACATGAATTCTTAAGGCTCTAGAATTCTTTAAGATTTCTGATATATTCTCGA...

...TGCTGTTCTTTTGAGGCCATTCAAGGCTTAATGACTA6CTGCTGTGAAATTCTTTAAACTTTTAGGCCGAGGCACTA...200bp...TTAGCTGACCATCTGGGAAAGGCGCTGTATTTCGACTGACATGAATTCTTAAGGCTCTAGAATTCTTTAAGATTTCTGATATATTCTCGA...
## Supplementary Table S1. LncCCAT1 expression and clinicopathological features in 80 patients with breast cancer

| Characteristics                      | Expression of LncCCAT1 | p value* |
|--------------------------------------|------------------------|----------|
|                                      | low        | high     |           |
| **Sex**                              |            |          |           |
| male                                 | 0          | 0        |           |
| female                               | 40         | 40       |           |
| **Age**                              |            |          | 0.239     |
| ≤ 60                                 | 31         | 35       |           |
| >60                                  | 9          | 5        |           |
| **Grade**                            |            |          | 0.024*    |
| I /II, well-differentiated           | 4          | 0        |           |
| II /II-III, moderately differentiated| 20         | 14       |           |
| III, poorly differentiated           | 16         | 26       |           |
| **Tumor histological**               |            |          | 0.006*    |
| Ductal carcinoma in situ             | 11         | 2        |           |
| Invasive ductal carcinoma            | 29         | 38       |           |
| **T Classification**                 |            |          | 0.058     |
| T1                                   | 12         | 5        |           |
| T2                                   | 27         | 30       |           |
| T3                                   | 1          | 5        |           |
| **N Classification**                 |            |          | 0.057     |
| N0                                   | 17         | 6        |           |
| N1                                   | 13         | 21       |           |
| N2                                   | 6          | 8        |           |
| N3                                   | 4          | 5        |           |
| **ER status**                        |            |          | 0.166     |
| Negative                             | 12         | 18       |           |
| Positive                             | 28         | 22       |           |
| **PR status**                        |            |          | 0.117     |
| Negative                             | 16         | 23       |           |
| Positive                             | 24         | 17       |           |
| **HER2 status**                      |            |          | 0.066     |
| Negative                             | 6          | 13       |           |
| Positive                             | 34         | 27       |           |
| **Tumor size (cm³)**                 |            |          | 0.004*    |
| ≤ 6                                  | 27         | 14       |           |
| >6                                   | 13         | 26       |           |
| **Lymph node metastasis**            |            |          | 0.000*    |
| Negative                             | 29         | 4        |           |
| Positive                             | 11         | 36       |           |

Median expression level was used as a cutoff to divide the 80 patients into LncCCAT1 low group (n = 40) and LncCCAT1 high group (n = 40).

Two-sided χ² test. * p<0.05
### Sequences of primers used for qRT-PCR

| Primer names | Sequences |
|--------------|-----------|
| LncCCAT1 forward | 5'-TCACTGACACACATCGACATTTGAAG-3' |
| LncCCAT1 reverse | 5'-GGAGAAAACGCCTAGCCATACAG-3' |
| hsa-miR-148a forward | 5'-AACATCAGCTTTCAGTGACTACA-3' |
| hsa-miR-148a reverse | 5'-TAATGTTGAGCTGACTCCAG-3' |
| hsa-miR-152 forward | 5'-TGAACCTGCTCAGTGACTGAGCA-3' |
| hsa-miR-152 reverse | 5'-TGATGTTGACAGCTGACTCCAG-3' |
| hsa-miR-204 forward | 5'-TTGATTCATTGGTGGTACTCT-3' |
| hsa-miR-204 reverse | 5'-TGATGTTGACAGCTGACTCCAG-3' |
| hsa-miR-211 forward | 5'-TATGGTTTTCAGTGACTCCAG-3' |
| hsa-miR-211 reverse | 5'-TATGGTTTTCAGTGACTCCAG-3' |
| Nanog forward | 5'-TCCCTCTCTCTCTACACTAAC-3' |
| Nanog reverse | 5'-CCCACAATCACAGCATAG-3' |
| Sox-2 forward | 5'-AACCAGATGCACAGCTACT-3' |
| Sox-2 reverse | 5'-GCTTACCCATGTCATGAAAC-3' |
| Oct-4 forward | 5'-GGAGTCAGCTCCCTCTCT-3' |
| Oct-4 reverse | 5'-CCAGGGTTTCTCCCTCTACG-3' |
| ALDH1A1 forward | 5'-GCACGCAAGCTTACCTGTC-3' |
| ALDH1A1 reverse | 5'-CCTCCTCAGGCTACGTTGAGA-3' |
| BTG2 forward | 5'-TGCGCTTAGGGAACATCTCT-3' |
| BTG2 reverse | 5'-TGCGCTTAGGGAACATCTCT-3' |
| ADAM9 forward | 5'-AAGTAACAGATCAGATGACCA-3' |
| ADAM9 reverse | 5'-GCAGCTTGAGTTGACCATGT-3' |
| FAT4 forward | 5'-AGACGGACTTATACAGGTTG-3' |
| FAT4 reverse | 5'-GGAACCTTACTACCGGTACCAT-3' |
| GDF15 forward | 5'-CTCCAGATTCCGAGTACCGTC-3' |
| GDF15 reverse | 5'-AGAGATACAGGATGACCGT-3' |
| GAPDH forward | 5'-GAGTCAACGGATTTGTCCT-3' |
| GAPDH reverse | 5'-TTGATTGTGGAGGTACCTC-3' |
| SPRY4 forward | 5'-CCAGGATGTCACCCACCA-3' |
| SPRY4 reverse | 5'-TGATGCTGCTGCTGTC-3' |
| CDH13 forward | 5'-AGTGGTCCATATCAATCAGCCAG-3' |
| CDH13 reverse | 5'-CGAGACCTTACAGCAGTACCT-3' |
| P15 forward | 5'-TCTCGTTGCGAGGAGTGCA-3' |
| P15 reverse | 5'-TAGCGAGGTACCCTGCAACG-3' |
| CASP14 forward | 5'-TGCACTGTTATTCCACGGTA-3' |
| CASP14 reverse | 5'-TCTCAGGTTGTGCTTTCTCG-3' |
| HPGD forward | 5'-CTGCACCATGCAGCTGACACG-3' |
| HPGD reverse | 5'-AGCGACTCAGCGTGTGTC-3' |
| IGFBP1 forward | 5'-TTGGGACGCCCAGTGACTC-3' |
| IGFBP1 reverse | 5'-TTGGCTAAGACTCTCCTACGACTC-3' |
Sequences of primers used for plasmid construction

| Forward/Reverse | Sequence |
|----------------|----------|
| P27 forward    | 5'-TAATTGGGCTCGGCTAACT-3' |
| P27 reverse    | 5'-TGCAGGTCGCTCTTATCC-3' |
| FAS forward    | 5'-CTTTTCGTAGCTGCTCTGTA-3' |
| FAS reverse    | 5'-CTCCCCAGAGCGTCTTTTGA-3' |
| KLF6 forward   | 5'-CTGCCGTCCTGGAGAGGT-3' |
| KLF6 reverse   | 5'-TCCACAGATCTTTCTGGCCTGTC-3' |
| IGFBP3 forward | 5'-AGGGGCAGACTGCTTTTCTT-3' |
| IGFBP3 reverse | 5'-TCTACTGTTACAGAATCCTTGTA-3' |
| ANXA2 forward  | 5'-AGTATAGGCTTTGACAGACCCAT-3' |
| ANXA2 reverse  | 5'-CAAGCAGCTGCGACTACAATA-3' |
| TCF4 forward   | 5'-CCAGGCTGATTCATCCCACTG-3' |
| TCF4 reverse   | 5'-CCAT1 forward 5'-CGCGGATCCGCCACCTTTAAATCATACCAATTGAA-3' |
| TCF4 reverse   | 5'-CCCAAGCTTCCAAGACTTAATATACTTATATTTA-3' |
| S1(1-785) forward | 5'-TAAACAGACTCATATAGGGATAAGGCGGAAATTTTCCCTGTGTG-3' |
| S1(1-785) reverse | 5'-TTTAATCATACCAATTGAAACCCGAG-3' |
| S2(630-1225) forward | 5'-TAATACGACTCACTATAGGGGAGAAGGGGTGAAAGGGACACTGG-3' |
| S2(630-1225) reverse | 5'-ACTGCCCTGAAACCTATATGCTGTT-3' |
| S3(1226-1883) forward | 5'-TAAACAGACTCATATAGGGGATGACAGGTTTGTGCTGAT-3' |
| S3(1226-1883) reverse | 5'-GAGGCAGGAGGGTGCTTGACAAATAA-3' |
| S4(1884-2504) forward | 5'-TAATACGACTCACTACCTAGGGGAGAAGGGGTGAAAGGGACACTG-3' |
| S4(1884-2504) reverse | 5'-GAACGTGACATCGCCGAGGATCTAGG-3' |
| S5(1884-2795) forward | 5'-TAATACGACTCACTATAGGGGAGAAGGGGTGAAAGGGACACTG-3' |
| S5(1884-2795) reverse | 5'-GAGGCAGGAGGGTGCTTGACAAATAA-3' |
| pmirGLO-CCAT1-WT (miR148a/152) forward | 5'-TCGAGAATGCCCTGTTAAGTAAACGAACGAAATTCAAAG |
| pmirGLO-CCAT1-WT (miR148a/152) reverse | 5'-CTGTGACATGCGAGGATCGGCTG-3' |
| pmirGLO-CCAT1-MUT (miR148a/152) forward | 5'-TCGAGAATGCCCTGTTAAGTAAACGAACGAAATTCAAAGGGAGAAGGGGTGAAAGGGACACTG |
| pmirGLO-CCAT1-MUT (miR148a/152) reverse | 5'-CTGTGACATGCGAGGATCGGCTG-3' |
| pmirGLO-CCAT1-WT (miR204/211) forward | 5'-TCGAGAATGCCCTGTTAAGTAAACGAACGAAATTCAAAG |
| pmirGLO-CCAT1-WT (miR204/211) reverse | 5'-CTGTGACATGCGAGGATCGGCTG-3' |
GGAAACAGGAGCAATCAT-3'

pmirGLO-CCAT1-WT (miR204/211) reverse
5’-CTAGATGATTGCTCCTGTGTTCTTTGGAATTTCGTTCGTTTTACTTAACAGGAGCAATCAT-3’

pmirGLO-CCAT1-MUT (miR204/211) forward
5’-TCGAGAATGCCCTGTGTTAAGACAGCTGGCGTGAGATCATCATCAT-3’

pmirGLO-CCAT1-MUT (miR204/211) reverse
5’-CTAGATGATTGCTCGGATACGCAGCCGGTACAGCTTCGTTTACTTAACAGGAGCAATCAT-3’

pmirGLO-TCF4-WT forward
5’-TCGAGTGTATCCCCATTAAAAAAGGGGAATGTGGCCTTTTTAGTTTTTT-3’

pmirGLO-TCF4-WT reverse
5’-CTAGAAAAACACACTAAAAAGGCAACATCCCTCTTTTTTTCTTTCTTTAGGTGTGTTT-3’

pmirGLO-TCF4-MUT forward
5’-TCGAGTGTATCCCCCGCAGCTGCTGCATGCATGTGGCCTTTTTAGTTTTTT-3’

pmirGLO-TCF4-MUT reverse
5’-CTAGAAAAACACACTAAAAAGGCAACACGCTGCATGCGCTGCAGTGGGGATACAC-3’

### Sequences of primers used for ChIP-qPCR

| Primer | Sequence |
|--------|----------|
| P1 forward | 5’-CTCTTTAACCAATGGGATTTC-3’ |
| P1 reverse | 5’-CACGCGAGCTGGTATGATG-3’ |
| P2 forward | 5’-TGATTCAACACATTAATCCTGC-3’ |
| P2 reverse | 5’-AGCATCTGGGGACAAACTCTCTCC-3’ |
| P3 forward | 5’-CCATGTAGTCTCTGTGTTTACTG-3’ |
| P3 reverse | 5’-AATCCCTGTGTTCTATGGAATGGCA-3’ |
| Neg forward | 5’-GTTTTTGCAATGGGAATTCC-3’ |
| Neg reverse | 5’-TGACGTCTTTTCTCCTGA-3’ |
| Protein   | Applications | Antibody                      | Origin    | dilution | Molecular weight |
|-----------|--------------|-------------------------------|-----------|----------|------------------|
| GAPDH     | WB           | D16H11, Cell Signaling Technology | Rabbit    | 1:1000   | 37 KD           |
| Sox2      | WB           | sc-365964, Santa cruz          | Mouse     | 1:500    | 34KD            |
| 4-Oct     | WB           | sc-101534, Santa cruz          | Mouse     | 1:500    | 52KD            |
| Nanog     | WB           | sc-293121, Santa cruz          | Mouse     | 1:500    | 40KD            |
| ALDH1A1   | WB           | sc-374076, Santa cruz          | Mouse     | 1:500    | 56KD            |
| DNMT1     | WB           | Ab19905, Abcam                 | Rabbit    | 1:1000   | 183KD           |
| TCF4      | WB           | 2565, Cell Signaling Technology | Rabbit    | 1:1000   | 58KD            |
| FAT4      | WB           | ab130076, Abcam                | Rabbit    | 1:1000   | 543KD           |
| CD44      | WB           | 3570, Cell Signaling Technology | Mouse     | 1:1000   | 80KD            |
| c-Myc     | WB           | 5605, Cell Signaling Technology | Rabbit    | 1:1000   | 57-65KD         |
| c-Jun     | WB           | 9165, Cell Signaling Technology | Rabbit    | 1:1000   | 43KD            |
| LEF1      | WB           | 2230, Cell Signaling Technology | Rabbit    | 1:1000   | 55KD            |
| MMP-7     | WB           | 3801, Cell Signaling Technology | Rabbit    | 1:1000   | 20-22KD         |
| Cyclin D1 | WB           | 2978, Cell Signaling Technology | Rabbit    | 1:1000   | 36KD            |
| TCF1/TCF7 | WB           | 2203, Cell Signaling Technology | Rabbit    | 1:1000   | 48.50KD         |
| β-catenin | WB, IF, IP   | 8480, Cell Signaling Technology | Rabbit    | 1:1000, 1:100, 1:25 | 92KD |
| Histone H3| WB           | 4499, Cell Signaling Technology | Rabbit    | 1:1000   | 17KD            |
| E-cadherin| WB           | 3195, Cell Signaling Technology | Rabbit    | 1:1000   | 135KD           |
| Vimentin  | WB           | ab92547, Abcam                 | Rabbit    | 1:1000   | 54KD            |
| ZEB-1     | WB           | 3396, Cell Signaling Technology | Rabbit    | 1:1000   | 200KD           |
| Slug      | WB           | 9585, Cell Signaling Technology | Rabbit    | 1:1000   | 30KD            |
| Snail     | WB           | 3879, Cell Signaling Technology | Rabbit    | 1:1000   | 29KD            |
| ANXA2     | WB, IF, IP   | ab41803, Abcam                 | Rabbit    | 1:1000, 1:100, 1:50 | 38KD |
| GSK-3β    | WB, IF, IP   | 9832, Cell Signaling Technology | Mouse     | 1:1000, 1:250, 1:50 | 46KD |
| Ago2      | RIP          | 03-110, Merck Millipore        | Mouse     | 1:10     | 100KD           |
| GFP       | RIP          | ab290, Abcam                   | Rabbit    | 1:20     | 28KD            |
| IgG       | CHIP, RIP    | ab18413, Abcam                 | Mouse     | 1:10     | 150KD           |
| CD44      | FC           | 559942, BD Pharmingen™         | Mouse     | 1:200    | 81KD            |
| CD24      | FC           | 555428, BD Pharmingen™         | Mouse     | 1:200    | 9KD             |
| ESA       | FC           | 25-9326-42, eBioscience        | Mouse     | 1:100    | 35KD            |
### Supplementary Table S4. Sequences of siRNAs and sgRNAs against specific targets

| RNA names | Sequences |
|-----------|-----------|
| FAT4-siRNA-1 | CTACGAAGATTTGGCTGTGA |
| FAT4-siRNA-2 | GACGCCAAGTCATCTTAGA |
| FAT4-siRNA-3 | GGTCTCGGTTCAGGTCAA |
| DNMT1-siRNA-1 | TCTTTGCAATTAGGCCTC |
| DNMT1-siRNA-2 | CAATGAGACTGACATCAA |
| DNMT1-siRNA-3 | GAGGCCTATAATGCAAGA |
| ANXA2-siRNA-1 | CGGCTGTATGACTCCATGA |
| ANXA2-siRNA-2 | GACCAACGCAGCAATGCA |
| ANXA2-siRNA-3 | GTCTGTCAAGCCTATACT |
| TCF4-siRNA-1 | GTTCTAGAAATGGAGGACA |
| TCF4-siRNA-2 | TGGCTATGCGAGAATGTG |
| TCF4-siRNA-3 | CAGACAGTATAATGGCAAA |
| LncCCAT-siRNA-1 | GTAGAAACACTATCACCTA |
| LncCCAT-siRNA-2 | CTAGAGAATCACCAATCT |
| LncCCAT-siRNA-3 | GAGTGAGATCAGCGTTATT |
| LncCCAT-ASO-1 | TCACCCAATCTACTCCCAT |
| LncCCAT-ASO-2 | AAGGTGCCGAGACATGAA |
| LncCCAT-ASO-3 | GTCGGCCCTAGCAAATGCA |
| sgRNA1 | GGTCCTTCTCCTGAATCCATCTGCTAGGACTGATCCTTGACACAT |
| sgRNA2 | TTAGCTCACCATCTGGAAAGGCTGATATTCTCTGCAC |
Figure 3K

Left (Wnt) MCF-7

Right (EMT)

MDA-MB-231

Left (Wnt) Right (EMT)

GAPDH

E-cadherin

VIMENTIN

ZEB-1

SNAIL

SLUG

CD44

c-Myc

c-Jun

LEF1

100kd
70kd
55kd
40kd

25kd
15kd
55kd
40kd

130kd
100kd
55kd
35kd

200kd
130kd
200kd
130kd

35kd
25kd
35kd
25kd

40kd
35kd
40kd
35kd

25kd
15kd

40kd
35kd
Figure S3A

Figure S3B

Figure S5C

Figure S5D
Molecular weight of all the protein:

**GAPDH**: 37 KD; **Sox2**: 34KD; **4-Oct**: 52KD; **Nanog**: 40KD; **ALDH1A1**: 56KD; **DNMT1**: 183KD; **TCF4**: 58KD; **FAT4**: 543KD; **CD44**: 80KD; **c-Myc**: 57-65KD; **c-Jun**: 43KD; **LEF1**: 55KD; **MMP-7**: 20-22KD; **Cyclin D1**: 36KD; **TCF1/TCF7**: 48,50KD; **β-catenin**: 92KD; **Histone H3**: 17KD; **E-cadherin**: 135KD; **Vimentin**: 54KD; **ZEB-1**: 200KD; **Slug**: 30KD; **Snail**: 29KD; **ANXA2**: 38KD; **GSK-3β**: 46KD.
Cell Line Authentication Report

Institution: CPU
Customer: Tingting Tang
Tel: 15295783878
Email: 1095477598@qq.com

Vendor: Cobioer Biosciences CO.,LTD
Attention: Taohua Jiang
Tel: 025-86880024
Email: jiangtaohua@cobioer.com
1. **Sample information:**

Cell pellets, No.: “MCF-7”

2. **Methods:**

a. Genomic DNA was extracted from the cell pellets provided by the customer.
b. Samples, together with positive and negative control were amplified using GenePrint System (Promega).
c. Amplified products were processed using the ABI3730xl Genetic Analyzer.
d. Data was analyzed by GeneMapper4.0 software and then compared with the ATCC, DSMZ or JCRB databases for reference matching.

3. **Results:**

STR profile

| Marker | Sample | Cobioer Database |
|--------|--------|------------------|
|        | Allele1 | Allele2 | Allele3 | Allele4 | Allele1 | Allele2 | Allele3 |
| D5S818 | 11      | 12      |         |         | 11      | 12      |
| D13S317| 11      | 11      |         |         | 11      | 11      |
| D7S820 | 8       | 9       |         |         | 8       | 9       |
| D16S539| 11      | 12      |         |         | 11      | 12      |
| VWA    | 14      | 15      |         |         | 14      | 15      |
| TH01   | 6       | 6       |         |         | 6       | 6       |
| AMEL   | X       | X       |         |         | X       | X       |
| TPOX   | 9       | 12      |         |         | 9       | 12      |
| CSF1PO | 10      | 10      |         |         | 10      | 10      |
| D12S391| 18      | 20      |         |         |         |         |
| FGA    | 23      | 24      | 25      |         |         |         |
| D2S1338| 21      | 23      |         |         |         |         |
| D21S11 | 30      | 30      |         |         |         |         |
| D18S51 | 14      | 14      |         |         |         |         |
| D8S1179| 10      | 14      |         |         |         |         |
| D3S1358| 16      | 16      |         |         |         |         |
| D6S1043| 12      | 18      |         |         |         |         |
| PENTAE | 7       | 12      |         |         |         |         |
| D19S433| 13      | 14      |         |         |         |         |
| PENTAD | 12      | 12      |         |         |         |         |
4. Conclusion

A. The STR results show that there are no four alleles on the main nine locus, there is certainly no cross contamination of human cells in this cell line.

B. The match percent between the sample and the STR database profile is **100%**, the cell name is **MCF-7**.

| STR   | D13S317 | D16S539 | D18S510 | D21S11 | TH01 | CSF1PO | vWA | Amel |
|-------|----------|----------|----------|---------|-------|--------|-----|-------|
| 11-12 | 11-11    | 9.9      | 11.82    | 14.15   | 0.0   | X,X    | 9.12| 50.30 |

Database Link: http://139.196.13.241:8081/index

**Note:**

1. The STR profile data was compared with the ATCC, DSMZ or JCRB databases, if the cell line is not included in the three institutions, the results are not correct. More information you provided would be useful for Cell Line Authentication.

2. Based on the ANSI Standard, cell lines with 100% match are considered to be “identical”; cell lines with \( \geq 80\% \) but less than 100% match are considered to be “related”.

Operator: Xiaomei Liu, Qin Wang

Leader: Wei Zhou

Date: 2018-05-09
Cell Line Authentication Report

Institution: CPU
Customer: Tingting Tang
Tel: 15295783878
Email: 1095477598@qq.com

Vendor: Cobioer Biosciences CO., LTD
Attention: Taohua Jiang
Tel: 025-86880024
Email: jiangtaohua@cobioer.com
1. Sample information:

   Cell pellets, No.: “MDA-MB-231”

2. Methods:

   a. Genomic DNA was extracted from the cell pellets provided by the customer.
   b. Samples, together with positive and negative control were amplified using GenePrint System (Promega).
   c. Amplified products were processed using the ABI3730xl Genetic Analyzer.
   d. Data was analyzed by GeneMapper4.0 software and then compared with the ATCC, DSMZ or JCRB databases for reference matching.

3. Results:

   STR profile

   | Marker        | Sample | Cobioer Database |
   |---------------|--------|------------------|
   |               | Allele1 | Allele2 | Allele3 | Allele4 | Allele1 | Allele2 | Allele3 |
   | D5S818        | 12      | 12      |         |         | 12      | 12      |
   | D13S317       | 13      | 13      |         |         | 13      | 13      |
   | D7S820        | 8       | 9       |         |         | 8       | 9       |
   | D16S539       | 12      | 12      |         |         | 12      | 12      |
   | VWA           | 15      | 18      |         |         | 15      | 18      |
   | TH01          | 7       | 9.3     |         |         | 7       | 9.3     |
   | AMEL          | X       | X       |         |         | X       | X       |
   | TPOX          | 8       | 9       |         |         | 8       | 9       |
   | CSF1PO        | 12      | 13      |         |         | 12      | 13      |
   | D12S391       | 17      | 18      |         |         |         |         |
   | FGA           | 22      | 23      |         |         |         |         |
   | D2S1338       | 20      | 21      |         |         |         |         |
   | D21S11        | 33.2    | 33.2    |         |         |         |         |
   | D18S51        | 11      | 16      |         |         |         |         |
   | D8S1179       | 13      | 13      |         |         |         |         |
   | D3S1358       | 16      | 16      |         |         |         |         |
   | D6S1043       | 18      | 18      |         |         |         |         |
   | PENTAE        | 11      | 11      |         |         |         |         |
   | D19S433       | 11      | 14      |         |         |         |         |
   | PENTAD        | 11      | 14      |         |         |         |         |
4. Conclusion

A. The STR results show that there are no four alleles on the main nine locus, there is certainly no cross contamination of human cells in this cell line.

B. The match percent between the sample and the STR database profile is 100%, the cell name is MDA-MB-231.

Database Link: http://139.196.13.241:8081/index

Note:

1. The STR profile data was compared with the ATCC, DSMZ or JCRB databases, if the cell line is not included in the three institutions, the results are not correct. More information you provided would be useful for Cell Line Authentication.

2. Based on the ANSI Standard, cell lines with 100% match are considered to be “identical”; cell lines with $\geq 80\%$ but less than 100% match are considered to be “related”.

Operator: Xiaomei Liu, Qin Wang

Leader: Wei Zhou

Date: 2018-05-15